(3R,4S,5S,6R)-2-[[4-[(4-cyclopropylphenyl)methyl]-5-methyl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S,5S,6R)-2-[[4-[(4-cyclopropylphenyl)methyl]-5-methyl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₀H₂₆N₂O₆
• 分子量: 390.4
• InChiKey: NGIVBPMUZZVGRW-HPUPVJTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  128
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE MALADIE MÉTABOLIQUE
  申请人：AVOLYNT

  公开号：WO2020242537A1

  公开（公告）日：2020-12-03

  The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2. In such dosage forms, SGLT1 is effective in the intestinal lumen, and is either not absorbed, or poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated by combined SGLT1 and SGLT2 oral dosage forms include disorders associated with abnormal accumulation of liver lipids, which may also be copresent with hyperglycemia. Combinations of SGLT1 and SGLT2 inhibitors are contemplated herein, particularly combinations